Invivyd Stock Forum

$Invivyd (IVVD.US)$ Invivyd Phase 3 Long-Term Exploratory Clinical Efficacy Data Shows PEMGARDA (Pemivibart) Provided Substantial Protection From Symptomatic COVID-19 Versus Placebo Over Six Months of Follow-Up, With No Additional Doses, In Immunocompetent Participants
GlobeNewswire· 12 mins ago
Following strong protection (84% relative risk reduction versus placebo) demonstrated through month 6 with pemivibart, CANOPY clinical trial participants were followed for an additional six-month pe...

$Invivyd (IVVD.US)$
Invivyd to Present PEMGARDA™ (pemivibart) Data at Infectious Disease Week (IDWeek) 2024
Invivyd (Nasdaq: IVVD) announced upcoming presentations of pemivibart data from its Phase 1 and Phase 3 clinical trials at IDWeek 2024 in Los Angeles, October 16-19, 2024. The presentations include:
An oral presentation on clinical efficacy endpoints from the Phase 3 CANOPY Study
A poster on results from a Phase 1 first-in-human study
A poster on pharmacokinetics and serum virus neutral...

$Invivyd (IVVD.US)$ i support this stock

$Invivyd (IVVD.US)$ 1.15 tomorrow?

New targets for next week:
$Invivyd (IVVD.US)$  - makes COVID antibodies, w/ a phase 3 trial completing soon.
$ReNew Energy Global (RNW.US)$ - unconventional and renewable energy company in India.
$Vivid Seats (SEAT.US)$ - Online marketplace for event tickets. Good competition vs. $Live Nation Entertainment (LYV.US)$
$Array Technologies (ARRY.US)$ Tracking equipment and software for solar panels, allowing them to increase efficiency following the sun through the day.

$Invivyd (IVVD.US)$
Invivyd Announces U.S. FDA Has Updated the PEMGARDA™ EUA Fact Sheet with Accurate SARS-CoV-2 Variant Susceptibility and PEMGARDA Activity Data
Invivyd (Nasdaq: IVVD) announced that the FDA has updated the Emergency Use Authorization (EUA) Fact Sheet for PEMGARDA™ (pemivibart) with accurate SARS-CoV-2 variant susceptibility data. The updated Fact Sheet, dated September 26, 2024, includes in vitro neutralization activity against dominant circulating variants, including KP.3....

$Invivyd (IVVD.US)$ Reuters
Just
Invivyd Announces U.S. FDA Has Updated the Pemgarda™ Eua Fact Sheet With Accurate Sars-Cov-2 Variant Susceptibility and Pemgarda Activity Data

$Invivyd (IVVD.US)$ huge climb expected now till dec 25th

$Invivyd (IVVD.US)$
Invivyd Provides Detailed Virology Data and Analysis of SARS-CoV-2 Structural Biology Predicting Anticipated Neutralization Activity for PEMGARDA™ (pemivibart)
Invivyd, Inc. (Nasdaq: IVVD) has provided detailed virology data and analysis of SARS-CoV-2 structural biology, predicting anticipated neutralization activity for PEMGARDA™ (pemivibart). Key points include:
Independent evaluation shows in vitro pseudovirus neutralization potency of PEMGARDA against KP.3.1.1 and LB....